Document Detail


Translocator protein PET imaging for glial activation in multiple sclerosis.
MedLine Citation:
PMID:  20872081     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Glial activation in the setting of central nervous system inflammation is a key feature of the multiple sclerosis (MS) pathology. Monitoring glial activation in subjects with MS, therefore, has the potential to be informative with respect to disease activity. The translocator protein 18 kDa (TSPO) is a promising biomarker of glial activation that can be imaged by positron emission tomography (PET). To characterize the in vivo TSPO expression in MS, we analyzed brain PET scans in subjects with MS and healthy volunteers in an observational study using [(11)C]PBR28, a newly developed translocator protein-specific radioligand. The [(11)C]PBR28 PET showed altered compartmental distribution of TSPO in the MS brain compared to healthy volunteers (p = 0.019). Focal increases in [(11)C]PBR28 binding corresponded to areas of active inflammation as evidenced by significantly greater binding in regions of gadolinium contrast enhancement compared to contralateral normal-appearing white matter (p = 0.0039). Furthermore, increase in [(11)C]PBR28 binding preceded the appearance of contrast enhancement on magnetic resonance imaging in some lesions, suggesting a role for early glial activation in MS lesion formation. Global [(11)C]PBR28 binding showed correlation with disease duration (p = 0.041), but not with measures of clinical disability. These results further define TSPO as an informative marker of glial activation in MS.
Authors:
Unsong Oh; Masahiro Fujita; Vasiliki N Ikonomidou; Iordanis E Evangelou; Eiji Matsuura; Erin Harberts; Yota Fujimura; Nancy D Richert; Joan Ohayon; Victor W Pike; Yi Zhang; Sami S Zoghbi; Robert B Innis; Steven Jacobson
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural     Date:  2010-09-25
Journal Detail:
Title:  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology     Volume:  6     ISSN:  1557-1904     ISO Abbreviation:  J Neuroimmune Pharmacol     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-07-01     Completed Date:  2011-09-30     Revised Date:  2012-01-16    
Medline Journal Info:
Nlm Unique ID:  101256586     Medline TA:  J Neuroimmune Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  354-61     Citation Subset:  IM    
Affiliation:
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Bldg 10 Rm 5C103, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetamides / diagnostic use
Adult
Aged
Biological Markers / analysis
Carbon Radioisotopes / diagnostic use
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis / immunology,  pathology*,  radionuclide imaging*
Neuroglia / immunology,  metabolism,  pathology*
Positron-Emission Tomography
Pyridines / diagnostic use
Radiopharmaceuticals / diagnostic use
Receptors, GABA / biosynthesis*
Grant Support
ID/Acronym/Agency:
ZIA MH002852-06/MH/NIMH NIH HHS; ZIA NS002853-18/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Acetamides; 0/Biological Markers; 0/Carbon Radioisotopes; 0/N-(2-methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide; 0/Pyridines; 0/Radiopharmaceuticals; 0/Receptors, GABA; 0/TSPO protein, human
Comments/Corrections
Erratum In:
J Neuroimmune Pharmacol. 2011 Sep;6(3):434
Note: Fujimura, Yota [added]; Richert, Nancy D [added]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Detection of ?-herpesviruses in Polish adult cord blood stem cell recipients by real-time PCR: singl...
Next Document:  Incidence of adverse drug events and medication errors in Japan: the JADE study.